Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Net Income (2016 - 2025)

Historic Net Income for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to -$16.9 million.

  • Northwest Biotherapeutics' Net Income fell 35.54% to -$16.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$73.4 million, marking a year-over-year decrease of 541.68%. This contributed to the annual value of -$74.3 million for FY2024, which is 2226.54% down from last year.
  • Latest data reveals that Northwest Biotherapeutics reported Net Income of -$16.9 million as of Q3 2025, which was down 35.54% from -$16.6 million recorded in Q2 2025.
  • In the past 5 years, Northwest Biotherapeutics' Net Income registered a high of -$11.7 million during Q3 2021, and its lowest value of -$22.5 million during Q2 2022.
  • Moreover, its 5-year median value for Net Income was -$16.9 million (2024), whereas its average is -$16.8 million.
  • Data for Northwest Biotherapeutics' Net Income shows a peak YoY increase of 7818.48% (in 2021) and a maximum YoY decrease of 14848.66% (in 2021) over the last 5 years.
  • Over the past 5 years, Northwest Biotherapeutics' Net Income (Quarter) stood at -$11.8 million in 2021, then tumbled by 64.0% to -$19.4 million in 2022, then rose by 15.54% to -$16.4 million in 2023, then dropped by 28.09% to -$21.0 million in 2024, then increased by 19.28% to -$16.9 million in 2025.
  • Its Net Income stands at -$16.9 million for Q3 2025, versus -$16.6 million for Q2 2025 and -$18.9 million for Q1 2025.